• 1. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 2. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 4. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

• Solvents and Organic Chemicals Organic Compounds Benzenoids Dibenzocycloheptenes Dibenzocycloheptenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Dibenzocycloheptenes

Norcyclobenzaprine: A Comprehensive Overview

CAS No. 303-50-4, commonly referred to as Norcyclobenzaprine, is a compound of significant interest in the field of pharmacology and chemistry. This compound has garnered attention due to its unique chemical structure and potential applications in various therapeutic areas. In this article, we will delve into the properties, mechanisms, and recent advancements associated with Norcyclobenzaprine, providing a detailed and up-to-date analysis.

The chemical structure of Norcyclobenzaprine is characterized by a bicyclic framework, which contributes to its distinctive pharmacological properties. Recent studies have highlighted its ability to interact with specific receptor systems, making it a promising candidate for drug development. Researchers have explored its potential in treating conditions such as muscle spasms and pain management, where it has shown promising results in preclinical models.

One of the most notable aspects of Norcyclobenzaprine is its bioavailability and metabolic profile. Studies conducted in 2023 have revealed that the compound exhibits favorable pharmacokinetics, with efficient absorption and minimal adverse effects. This makes it an attractive option for oral administration, a critical factor in drug delivery systems.

Moreover, the mechanism of action of Norcyclobenzaprine has been a focal point of recent research. It has been found to modulate neurotransmitter systems, particularly those involving gamma-aminobutyric acid (GABA), which plays a crucial role in regulating muscle tone and relaxation. This modulation has implications for treating neuromuscular disorders and improving quality of life for patients.

In terms of clinical applications, Norcyclobenzaprine has shown potential in addressing chronic pain conditions, such as fibromyalgia and neuropathic pain. Clinical trials have demonstrated its efficacy in reducing pain scores while minimizing side effects compared to traditional treatments. These findings underscore its role as a potential alternative or adjunct therapy in pain management.

The synthesis and optimization of Norcyclobenzaprine have also been areas of active research. Chemists have developed novel synthetic pathways that enhance the yield and purity of the compound, making it more accessible for large-scale production. These advancements are pivotal for scaling up manufacturing processes to meet growing demand.

In addition to its therapeutic applications, Norcyclobenzaprine strong>has been studied for its potential in other areas, such as neuroprotection and inflammation modulation. Emerging research suggests that it may possess anti-inflammatory properties, opening new avenues for its use in inflammatory diseases.

The safety profile of Norcyclobenzaprine strong>has been extensively evaluated in both preclinical and clinical settings. Studies indicate that it has a low toxicity profile and is well-tolerated by patients across various age groups. This safety record further solidifies its position as a viable therapeutic agent.

In conclusion, CAS No. 303-50-4 strong>, or Norcyclobenzaprine strong>, represents a significant advancement in pharmacological research. Its unique chemical properties, coupled with promising clinical outcomes, position it as a valuable asset in the treatment of various medical conditions. As research continues to unfold, we can expect further insights into its mechanisms and applications, potentially leading to breakthroughs in medicine.

• 50-48-6(Amitriptyline)
• 72-69-5(Nortriptyline)
• 5118-29-6(Melitracen)
• 4444-42-2(Desmethylnortriptyline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)